Jose Antonio Sanchez Alcazar is Full professor at Pablo de Olavide University (Seville, Spain).  He is a Principal Investigator at Andalusian Center for Developmental Biology (CABD). His research group proposes that precision or personalized medicine approaches can be an alternative to find potential therapies in genetic rare diseases. To this end, patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments. His group has developed three platforms for performing precision or personalized medicine in rare diseases: Braincure for neurodegenerative diseases; Mitocure platform for mitochondrial diseases; and Myocure for congenital myopathies.